Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, State Key Laboratory for Oncogenes and Related Genes, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, 145 Middle Shandong Road, Shanghai 200001, China.
Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, State Key Laboratory for Oncogenes and Related Genes, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, 145 Middle Shandong Road, Shanghai 200001, China.
Autoimmun Rev. 2017 Aug;16(8):875-882. doi: 10.1016/j.autrev.2017.05.018. Epub 2017 May 28.
There is increased interest and recognition of the clinical variants of Sclerosing Cholangitis (SC) namely IgG4-SC, PSC/AIH overlap and PSC. For most Centers, the characteristic of IgG4-SC has not been thoroughly clinically compared with other sclerosing cholangitis variants. Further there are relatively few PSC/AIH overlap patients and the clinical outcome is not well characterized, especially for the PSC/AIH overlap syndrome. Our objective herein is to clarify the differences and similarities of the natural history of IgG4-SC, the PSC/AIH overlap and PSC alone. We also place in perspective the diagnostic value of serum IgG4 for IgG4-SC and investigate biomarkers for predicting the prognosis of sclerosing cholangitis. In this study, we took advantage of our large and well-defined patient cohort to perform a retrospective cohort study including 57 IgG4-SC, 36 PSC/AIH overlap patients, and 55 PSC patients. Firstly, as expected, we noted significant differences among immunoglobulin profiles and all patients exhibited similar cholestatic profiles at presentation. Cirrhotic events were found in 20 of total 57 IgG4-SC, 15 of 36 PSC/AIH overlap, and 18 of 55 PSC patients. Serum IgG4 was elevated in 92.65% of IgG4-SC patients with an 86% sensitivity and 98% specificity for diagnosis. IgG4-SC patients had a better treatment response at 6-month and 1-year than PSC/AIH patients, while the latter responded better with steroids than PSC patients. Importantly the adverse outcome-free survival of IgG4-SC patients was reduced, unlike earlier reports, and therefore similar to the PSC/AIH overlap syndrome. Serum IgG and total bilirubin were useful to predict long-term survival of IgG4-SC and PSC/AIH, respectively. In conclusion, serum IgG4≧1.25 ULN shows an excellent predictability to distinguish IgG4-SC among SC patients. IgG4-SC appears to be immune-mediated inflammatory process, while PSC/AIH overlap more tends to be cholestatic disease.
人们对硬化性胆管炎(SC)的临床变异型(如 IgG4-SC、PSC/AIH 重叠和 PSC)的兴趣和认识日益增加。对于大多数中心来说,IgG4-SC 的特征尚未与其他硬化性胆管炎变异型进行彻底的临床比较。此外,PSC/AIH 重叠患者相对较少,临床结局也不明确,尤其是 PSC/AIH 重叠综合征。我们的目的是阐明 IgG4-SC、PSC/AIH 重叠和单独 PSC 的自然史的异同。我们还从诊断价值的角度看待血清 IgG4 对 IgG4-SC 的作用,并研究预测硬化性胆管炎预后的生物标志物。在这项研究中,我们利用我们的大型和明确界定的患者队列进行了一项回顾性队列研究,其中包括 57 例 IgG4-SC、36 例 PSC/AIH 重叠患者和 55 例 PSC 患者。首先,正如预期的那样,我们注意到免疫球蛋白谱存在显著差异,所有患者在发病时均表现出类似的胆汁淤积谱。在总共 57 例 IgG4-SC 患者中发现了 20 例肝硬化事件,在 36 例 PSC/AIH 重叠患者中发现了 15 例,在 55 例 PSC 患者中发现了 18 例。92.65%的 IgG4-SC 患者血清 IgG4 升高,诊断的敏感性为 86%,特异性为 98%。与 PSC/AIH 患者相比,IgG4-SC 患者在 6 个月和 1 年时的治疗反应更好,而后者对类固醇的反应优于 PSC 患者。重要的是,与之前的报道不同,IgG4-SC 患者的无不良预后生存率降低,因此与 PSC/AIH 重叠综合征相似。血清 IgG 和总胆红素分别有助于预测 IgG4-SC 和 PSC/AIH 的长期生存。总之,血清 IgG4≧1.25ULN 显示出极好的预测能力,可区分 SC 患者中的 IgG4-SC。IgG4-SC 似乎是免疫介导的炎症过程,而 PSC/AIH 重叠更倾向于胆汁淤积性疾病。